A systematic review of economic studies on biological agents used to treat Crohn's disease

Inflammatory Bowel Diseases

Volumn 19, Issue 12, 2013, Pages 2673-2694

  Tang, Derek H ^a   Harrington, Amanda R ^a   Lee, Jeannie K ^a   Lin, Mark ^b   Armstrong, Edward P ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Biologics; Cost; Cost effective; Crohn's disease; Systematic review

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB; MERCAPTOPURINE; METRONIDAZOLE; NATALIZUMAB;

BODY WEIGHT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG COST; DRUG DOSE ESCALATION; DRUG INDUSTRY; DRUG TREATMENT FAILURE; ECONOMICS; EMBASE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; INTERVENTION STUDY; MEDICAL SERVICE; MEDLINE; MONOTHERAPY; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; QUASI EXPERIMENTAL STUDY; RECURRENCE RISK; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THERAPY; TREATMENT DURATION; TREATMENT RESPONSE;

BIOLOGICAL FACTORS; COLITIS, ULCERATIVE; COST-BENEFIT ANALYSIS; CROHN DISEASE; HEALTH CARE COSTS; HUMANS;

EID: 84888365898     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e3182916046     Document Type: Review

References (68)

1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126:1504-1517.
2. Jacobsen BA, Fallingborg J, Rasmussen HH, et al. Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978-2002. Eur J Gastroenterol Hepatol. 2006;18:601-606.
3. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic istribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424-1429.
4. Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004;99:91-96.
5. Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644-659.
6. Lichtenstein GR, Hanauer SB, Sandborn WJ, et al. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-483.
7. Behm BW, Bickston SJ. Tumour necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2008;(23):CD006893.
8. MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2007;(24):CD006097.
9. Bernstein CN, Fried M, Krabshuis JH, et al. World gastroenterology organization practice guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 2010;16:112-124.
10. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354:924-933.
11. Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohn's disease in the United States and ther Western countries: a systematic review. Curr Med Res Opin. 2008;24:319-328.
12. Bodger K. Cost of illness of Crohn's disease. Pharmacoeconomics. 2002; 20:639-652.
13. Feagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol. 2000;95: 1955-1960.
14. Bodger K. Cost effectiveness of treatment for inflammatory bowel disease. Pharmacoeconomics. 2011;29:387-401.
15. Fleurence R, Spackman E. Cost-effectiveness of biologic agents for treatment of autoimmune disorders: structured review of the literature. J Rheumatol. 2006;33:2124-2131.
16. Ghosh S. Management of Crohn's disease from efficacy, quality of life and health economic perspectives. Expert Rev Pharmacoecon Outcomes Res. 2003;3:587-598.
17. Feagan BG. Review article: economic issues in Crohn's disease - assessing the effects of new treatments on health-related quality of life. Ailment Pharmacol Ther. 1999;13:29-37.
18. Bodger K. Economic implications of biological therapies for Crohn's disease: review of infliximab. Pharmacoeconomics. 2005;23:875-888.
19. Clark W, Raftery J, Song F, et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. Health Technol Assess. 2003;7:1-67.
20. Dretzke J, Edlin R, Round J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technol Assess. 2011;15:1-244.
21. Feagan BG, Enns R, Fedorak RN, et al. Infliximab for treatment of Crohn's disease: efficacy, safety and pharmacoeconomics. Can J Clin Pharmacol. 2001;8:188-198.
22. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 5.0.2. The Cochrane Collaboration. Chichester, UK: John Wiley & Sons, 2009.
23. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313:275-283.
24. Bridges JF, Onukwugha E, Mullins CD. Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50,000 threshold in the US. Pharmacoeconomics. 2010;28:175-184.
25. Arseneau KO, Cohn SM, Cominelli F, et al. Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology. 2001;120:1640-1656.
26. Marshall JK, Blackhouse G, Goeree R, et al. Infliximab for the Treatment of Crohn's disease: A Systematic Review and Cost Utility Analysis. Technology Report No. 24. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessment (CCOHTA);2002.
27. Jaisson-Hot I, Flourie B, Descos L, et al. Management for severe Crohn's disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care. 2004;20:274-279.
28. Kaplan GG, Hur C, Korzenik J, et al. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a costeffectiveness analysis. Aliment Pharmacol Ther. 2007;26:1509-1520.
29. Lindsay J, Punekar YS, Morris J, et al. Health-economic analysis: costeffectiveness of scheduled maintenance treatment with infliximab for Crohn's disease - modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther. 2008;28:76-87.
30. Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for crohn's disease: Markov cohort analyses incorporating united kingdom patient-level cost data. Aliment Pharmacol Ther. 2009;30:265-274.
31. Loftus EV Jr, Johnson SJ, Yu AP, et al. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. Eur J Gastroenterol Hepatol. 2009;21:1302-1309.
32. Yu AP, Johnson S, Wang ST, et al. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease. Pharmacoeconomics. 2009;27:609-621.
33. Punekar YS, Sunderland T, Hawkins N, et al. Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease. Value Health. 2010;13:188-195.
34. Ananthakrishnan AN, Hur C, Korzenik JR. Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis. Dig Dis Sci. 2011;57:472-480.
35. Ananthakrishnan AN, Hur C, Juillerat P, et al. Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis. Am J Gastroenterol. 2011;106:2009-2017.
36. Tang DH, Armstrong EP, Lee JK. A cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease. Pharmacotherapy. 2012; 32:515-526.
37. Blackhouse G, Assasi N, Xie F, et al. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease. J Crohns Colitis. 2012;6:77-85.
38. Jewell DP, Satsangi J, Lobo A, et al. Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol. 2005;17:1047-1052.
39. Ollendorf DA, Lidsky L. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially insured setting. Am J Ther. 2006;13:502-506.
40. Saro C, da la Coba C, Casado MA, et al. Resource use in patients with Crohn's disease treated with infliximab. Aliment Pharmacol Ther. 2007; 10:1313-1323.
41. Wu EQ, Mulani PM, Yu AP, et al. Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective. Value Health. 2008;11:820-829.
42. Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. Adv Ther. 2009;26:936-946.
43. Sprakes MB, Ford AC, Suares NC, et al. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience. Aliment Pharmacol Ther. 2010;32:1357-1363.
44. Loomes DE, Teshima C, Jacobs P, et al. Health care resource use and costs in Crohn's disease before and after infliximab therapy. Can J Gastroenterol. 2011;25:497-502.
45. Kappelman MD, Rifas-Shiman SL, Porter C, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907-1913.
46. Mesterton J, Jönsson L, Almer SH, et al. Resource use and societal costs for Crohn's disease in Sweden. Inflamm Bowel Dis. 2009;15: 1882-1890.
47. Buchanan J, Wordsworth S, Ahmad T, et al. Managing the long term care of inflammatory bowel disease patients: the cost to European health care providers. J Crohns Colitis. 2011;5:301-316.
48. Sandborn WJ, Colombel JF, Schreiber S, et al. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis. 2011;17:141-151.
49. Binion DG, Louis E, Oldenburg B, et al. Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysis. Can J Gastroenterol. 2011;25:492-496.
50. Louis E, Lofberg R, Reinisch W, et al. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial. J Crohns Colitis. 2013;7:34-43.
51. Bakhshai J, Bleu-Lainé R, Jung M, et al. The cost effectiveness and budget impact of natalizumab for formulary decision. J Med Econ. 2010;13:63-69.
52. Nahar IK, Shojania K, Marra CA, et al. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann Pharmacother. 2003;37:1256-1265.
53. Thomas T, Cohen RD. Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies. Expert Rev Gastroenterol Hepatol. 2007;1:101-112.
54. Di Sabatino A, Liberato L, Marchetti M, et al. Optimal use and cost effectiveness of biologic therapies in inflammatory bowel disease. Intern Emerg Med. 2011;6:S17-S27.
55. Park KT, Bass D. Inflammatory bowel disease-attributable costs and costeffective strategies in the United States: a review. Inflamm Bowel Dis. 2011;17:1603-1609.
56. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106:685-698.
57. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-413.
58. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008;135:1493-1499.
59. Briggs A, Schulpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford, United Kingdom: Oxford University Press; 2006.
60. Humira Prescribing Information [Internet]. Chicago, IL: Abbott Laboratories; 2011. Available at: http://www.rxabbott.com/pdf/humira.pdf. Accessed September 2012. Updated March 2011.
61. Summary of the European Public Assessment Report for Humira. London, United Kingdom: European Medicines Agency; 2012. Available at: http:// www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/ 000481/WC500050865.pdf. Accessed September 2012. Updated march 2012.
62. Meltzer MI. Introduction to health economics for physicians. Lancet. 2001;358:993-998.
63. Chaparro M, Panes J, Garcia V, et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. J Clin Gastroenterol. 2011;45:113-118.
64. Loftus EV Jr, Pan X, Zurawski P, et al. Adalimumab real-world dosage pattern and predictors of weekly dosing: patients with Crohn's disease in the United States. J Crohns Colitis. 2011;5:550-554.
65. Kane S, Dixon L. Adherence rates with infliximab therapy in Crohn's disease. Aliment Pharmacol Ther. 2006;24:1099-1103.
66. Billioud V, Laharie D, Filippi J, et al. Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience. Inflamm Bowel Dis. 2011; 17:152-159.
67. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8:165-178.
68. Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol. 2009;27:2111-2113.